title: Perceived Risk Among Human Immunodeficiency Virus Serodiscordant Couples in East Africa Taking Oral Pre-Exposure Prophylaxis.
abstract: Perceived risk of human immunodeficiency virus (HIV) infection is thought to drive low adherence in pre-exposure prophylaxis (PrEP) trials. We explored the level of perceived risk of incident HIV infection in the Partners PrEP Study, in which adherence was generally high.
  
  
  
  A cross-sectional questionnaire assessed perceived risk of HIV at 12 months after enrollment. Logistic regression was used to analyze the relationship between perceived risk and other demographic and behavioral variables.
  
  
  
  Three thousand two hundred twenty-six couples from the Partners PrEP Study were included in this analysis. Only 15.4% of participants reported high or moderate perceived risk. Participants at high risk of acquiring HIV were slightly more likely to report high perceived risk (odds ratio, 1.60; 95% confidence interval, 1.30-1.95; P < 0.001); nevertheless, only 20% of participants with high-risk reported high perceived risk.
  
  
  
  Participants reported low perceived risk of HIV but were adherent to PrEP. Perceptions of risk are likely socially determined and more complex than Likert scale questionnaires capture.
authors.affiliation: From the *Department of Epidemiology, †Department of Anthropology, ‡Department of Global Health, University of Washington, Seattle, WA; §Kenya Medical Research Institute; ‖Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya; ¶International Clinical Research Center, University of Washington, Seattle, WA; **Kabwohe Clinical Research Center, Kabwohe, Uganda; ††Department of Medicine, University of Washington, Seattle, WA.
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Carroll
authors.forename: Renee
authors.initials: R
authors.lastname: Heffron
authors.forename: Nelly
authors.initials: N
authors.lastname: Mugo
authors.forename: Kenneth
authors.initials: K
authors.lastname: Ngure
authors.forename: Patrick
authors.initials: P
authors.lastname: Ndase
authors.forename: Stephen
authors.initials: S
authors.lastname: Asiimwe
authors.forename: Connie
authors.initials: C
authors.lastname: Celum
authors.forename: Jared M
authors.initials: JM
authors.lastname: Baeten
mesh_terms: D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000097:blood* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control*; D018023:HIV Seronegativity; D020010:Heterosexuality; D006801:Humans; D007630:Kenya; D008297:Male; D055118:Medication Adherence; D010465:Perception; D065129:Pre-Exposure Prophylaxis; D012306:Risk; D012747:Sexual Partners; D011795:Surveys and Questionnaires; D000068698:Tenofovir / Q000097:blood / Q000627:therapeutic use; D014454:Uganda; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D000068698:Tenofovir